Ann: Initiation of Phase 2 Trial for Efti in Soft Tissue Sarcoma, page-8

Many variables in trying to value a immuno-oncology drug.

Below based on US Bio research specialist. A rough guide only.

Start of each phase - oncology single molecule valuation estimation ($US)

Phase 1 $105M - Probability of FDA approval: 12%
Phase 2 $285m - probability of FDA approval: 20%
Phase 3 $1,248m - probability of FDA approval: 56%
Completion phase 3 - FDA submission - $3,500m
FDA approved and commercialisation - $4,500m+

Above could be multiplied by x% based on multiple indications.

So, what's Efti worth right now?